Navigation Links
Diabetes Medications Don't Lower Inflammation

Metformin, insulin have little effect on risk factor for heart disease, study finds

TUESDAY, Sept. 15 (HealthDay News) -- In people with newly diagnosed type 2 diabetes, the glucose-lowering medications metformin and insulin don't appear to reduce the inflammation associated with heart disease, new research suggests.

Even though these medications helped reduce glucose levels, the researchers found they didn't affect inflammatory markers any more than a placebo drug did, according to a study published in the Sept. 16 issue of the Journal of the American Medical Association.

"Heart disease is one of the many co-morbidities associated with diabetes," explained study author Dr. Aruna Pradhan, an assistant professor at the Harvard Medical School and Brigham and Women's Hospital in Boston, and a cardiologist at the VA Boston Medical Center. "We thought by lowering glucose levels that we would also address inflammation. But, we found that going lower in glucose levels doesn't impact inflammation, which is a risk factor for heart disease."

This study comes on the heels of other recent studies on diabetes and cardiovascular disease. Some suggested that intensive glucose control couldn't affect heart disease risk, while a recent meta-analysis suggests that good blood sugar levels could reduce death from heart attack, according to background information in Pradhan's study.

Almost 24 million Americans have diabetes, mostly type 2 diabetes, according to the American Diabetes Association. Risk factors for developing the disease include being overweight and being over 40, though younger and thinner people can also develop the disease. In type 2 diabetes, the body either doesn't produce enough insulin or can't use insulin effectively.

The current study included 500 men and women with type 2 diabetes diagnosed two years earlier on average. Slightly more women than men were included, and most of the study volunteers had a body-mass index above 30, which is considered obese. The majority of the study participants were white, and about one-quarter of the group were smokers.

The volunteers were randomized into one of four groups: placebo alone, placebo plus insulin glargine (Lantus), metformin (an oral anti-diabetes medication) alone or metformin plus insulin glargine. Study volunteers also received advice on diet and weight.

Overall, the volunteers lost an average of 3.2 pounds during the 14-week study, except for the insulin and placebo group.

As for markers of inflammation, the researchers found reductions in inflammation (as measured through levels of C-reactive protein, IL-6 and tumor necrosis factor receptor 2) for all of the groups. The insulin-plus-placebo group, however, had the smallest reduction in inflammatory markers. For example, C-reactive protein levels went down in the placebo group by 19 percent, in the metformin group by 16 percent and the metformin and insulin group by 20 percent. However, the insulin plus placebo group went down just 3 percent.

Pradhan said the researchers adjusted the data to account for the weight loss, and still found a similar effect. She said it may be that the weight changes affected the distribution of fat, and that abdominal fat tends to have more of an effect on inflammation.

"While these two agents didn't lower inflammation [any more than the placebo], they did lower glucose levels and are excellent drugs for preventing microvascular outcomes, like eye and kidney diseases," said Pradhan. The findings also confirm that diet and exercise can affect inflammation levels, she added.

"While this is a well-conducted study, there are no big surprises here," said Dr. Vivian Fonseca, chief of endocrinology at Scott & White Clinic in Temple, Tex., and Texas A&M Health Sciences Center, College Station. "There are many drugs that benefit people and reduce cardiovascular risk without decreasing inflammation, and there are drugs that reduce inflammation that have sometimes killed people from cardiovascular disease."

"We're trying to look at this problem the other way," said Fonseca. She and other researchers across the country will test an anti-inflammatory medication, salsalate, to see if lowering inflammation directly can have an impact on blood glucose levels.

More information

Learn more about preventing type 2 diabetes from the American Diabetes Association.

SOURCES: Aruna D. Pradhan, M.D., M.P.H., assistant professor, Harvard Medical School and Brigham and Women's Hospital, Boston, and cardiologist, VA Boston Medical Center; Vivian Fonseca, M.D., professor and chief, endocrinology, Scott & White Clinic, Temple, Texas, and Texas A & M Health Sciences Center, College Station; Sept. 16, 2009, Journal of the American Medical Association

Copyright©2009 ScoutNews,LLC.
All rights reserved  

Related medicine news :

1. GENova Biotherapeutics and Prime BioResearch signs LOI on diabetes and cancer cure
2. Diabetes Drug Kills Cancer Stem Cells in Combination Treatment in Mice
3. Common Diabetes Drug May Fight Cancer
4. Discovery May Pave Way to Better Diabetes Care
5. Inner workings of molecular thermostat point to pathways to fight diabetes, obesity
6. Chicago Bears Quarterback Jay Cutler, Eli Lilly and Company and the American Diabetes Association Team Up to Fund Diabetes Camp Scholarships Through "Touchdowns for Diabetes"
7. Dr. Eliscer Guzman, with The Mount Sinai Medical Center, Join Forces to Celebrate the Community Diabetes and Cardiovascular Care Programs Graduation Ceremony on September 16th
8. CureDM Awarded 2009 Diabetes Product Innovation of the Year by Frost and Sullivan
9. Independence Blue Cross Announces Its Second Year Sponsorship of Step Out: Walk to Fight Diabetes
10. Team reveals molecular mechanism underlying a form of diabetes
11. Newly Published Clinical Study Finds New Commercial Diet Program Superior to Standard Protocol for Diabetes Weight Loss and Blood Sugar Control
Post Your Comments:
Related Image:
Diabetes Medications Don't Lower Inflammation 
(Date:11/30/2015)... DIAMOND BAR, CALIF. (PRWEB) , ... ... ... Technology, Inc. ( ), a leading provider of enterprise Time and ... Certified Partner status in the Microsoft Partner Program with competencies in the ...
(Date:11/30/2015)... Durham, NC (PRWEB) , ... November 30, 2015 ... ... Orthopedic practices in 2016. In 2016, expected coding changes are likely to include ... prolonged service codes. It’s not easy to understand the effects of code changes ...
(Date:11/29/2015)... Metamora, Michigan (PRWEB) , ... ... ... is once again accredited by the American Institute of Ultrasound in Medicine! ... allows practices to demonstrate that they meet or exceed nationally recognized standards ...
(Date:11/29/2015)... PA (PRWEB) , ... November 29, 2015 , ... While ... with kneeling or provide ready access to exercise weights. Fortunately, an inventor from Uniontown, ... for THE TOMMY WALKER to enhance the benefits of a standard walker to improve ...
(Date:11/28/2015)... ... 28, 2015 , ... StatRad , a leading provider ... and Claude Hooton to its board of directors. The announcement comes as the ... Annual Meeting and continues to strategically transform its focus from being a teleradiology ...
Breaking Medicine News(10 mins):
(Date:11/29/2015)... and NUREMBERG, Germany , ... meeting, innovation leader Ziehm Imaging invites attendees to experience ... on the market. The highlight on display is Ziehm ... flat-panel technology that provides a 16 cm edge length ... Vision RFD Hybrid Edition, the first fully motorized mobile ...
(Date:11/27/2015)... --> --> ... The potential to save costs, improve treatment quality and ... fully exploited as yet. Here, particular emphasis is placed ... mobile tablet or directly at the patients, bedside. ... ) -->      (Photo: ...
(Date:11/26/2015)... PUNE, India , November ... --> ... / personal emergency response system ... grow steadily for 5 years ... growing region expected to see ...
Breaking Medicine Technology: